ZURICH – Roche has launched a global cancer immunotherapy Centers of Research Excellence network, saying it will invest up to 100 million Swiss francs ($100.3 million) in the project.
-
Immunotherapy drug sustains father of 5 living with stage 4 bladder cancer
-
Immunotherapy improves survival in head and neck cancer patients, study finds
-
Sean Parker sets up $250 million cancer immunotherapy collaboration
The research network of 21 academic centers around the world is intended to support basic and clinical research collaboration to advance the science of cancer immunotherapy, the Basel-based drugmaker said on Tuesday.